Melanoma With Confirmed Progression: Effect of Lenvatinib Plus Pembrolizumab
Source: Physicians Weekly, February 2023
The following is a summary of “Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination,” published in the January 2023 issue of Oncology by Arance, et al.
Melanoma that advances on inhibitors of programmed cell death protein-1 (PD-1) or its ligand (PD-L1) requires effective therapy. Therefore, for a study, researchers carried out phase II LEAP-004 research to assess the effectiveness of the combination of the PD-1 inhibitor pembrolizumab with the multikinase inhibitor lenvatinib.
Lenvatinib 20 mg orally once daily plus approximately ?35 doses of pembrolizumab 200 mg intravenously once every 3 weeks were given to eligible patients with unresectable stage III–IV melanoma who had confirmed progressive disease (PD) within 12 weeks of the last dose of a PD-1/L1 inhibitor, alone or in combination with other therapies, including cytotoxic T-cell lymphocyte–associated antigen 4 (CTLA-4) inhibitors. The treatment was continued until PD or unacceptable toxicity. The objective response rate (ORR), according to RECIST, version 1.1, by independent central review, was the main outcome measure.